Skip to main content

Table 2 Characteristics of substances subject to patent challenges

From: Patent challenges and factors associated with successful patent challengers under the patent linkage system: recent evidence from South Korea after the Korea United States free trade agreement

  Substances Challenged by
one manufacture
Challenged by
less than 5 manufacturers
Challenged by
more than 8 manufacturers
  39 16 (41 %) 11 (28 %) 12 (31 %)
Route
  Oral 32 9 (28 %) 11 (34 %) 12 (38 %)
  Injection 3 3 (100 %) 0 (0 %) 0 (0 %)
  Others 4 4 (100 %) 0 (0 %) 0 (0 %)
ATC classification
  A/B/C 18 4 (22 %) 6 (33 %) 8 (44 %)
  J/L 6 3 (50 %) 2 (33 %) 1 (17 %)
  M/N 4 1 (25 %) 1 (25 %) 2 (50 %)
  Others 11 8 (73 %) 2 (18 %) 1 (9 %)
Reimbursed
  No 10 1 (10 %) 4 (40 %) 5 (50 %)
  Yes 29 15 (52 %) 7 (24 %) 7 (24 %)
Approved year
  1994–2005 8 4 (50 %) 4 (50 %) 0 (0 %)
  2006–2010 13 5 (38 %) 3 (23 %) 5 (38 %)
  2011–2016 18 7 (39 %) 4 (22 %) 7 (39 %)
Market size (million KRW)
  < 100,000 9 5 (56 %) 1 (11 %) 3 (33 %)
  100,000-700,000 14 8 (57 %) 4 (29 %) 2 (14 %)
  700,000 ≤ 16 3 (19 %) 6 (38 %) 7 (44 %)
  1. ATC Anatomical Therapeutic Chemical; KRW Korean won